Moderna Reports $1.3 Billion Q3 Revenue, $162 Million Net Income
Moderna reported Q3 2026 revenue of $1.313B, up 29% YoY, and net income of $162M. EPS was $0.38, reversing a prior-year loss. The company raised its 2026 revenue growth outlook to 15–25% and expects year-end cash of $8.1B–$8.3B. Key drivers included international COVID vaccine sales and FDA approvals for mFLUSIVA.
How this was made
The 30-second read
Why it matters
The earnings beat and raised outlook are likely to drive short‑term buying, while the mixed pipeline news adds nuance.
Market read
Moderna's strong earnings and guidance lift sentiment in the biotech sector, with potential spillover to peers.
What to watch
The failed norovirus vaccine cohort and the need for additional regulatory submissions could temper upside.
Background
The article summarizes Moderna's Q3 2026 earnings release filed via an 8‑K, including product approvals and guidance updates.
Ticker impact
Moderna reported Q3 2026 revenue of $1.313B, up 29% YoY, net income $162M, and raised its 2026 revenue outlook to 15%-25%.
likely upward pressure as the market prices in the revenue beat and higher outlook.
The company posted a sizable profit after a loss year‑over‑year and lifted its growth guidance, which typically drives buying interest.
Market effects
Biotech and vaccine manufacturers may see renewed investor interest on the back of Moderna's strong flu vaccine approvals.
U.S. and international markets could benefit from increased confidence in vaccine pipelines.
Moderna's FDA and Canadian approvals highlight broader trends in mRNA vaccine adoption worldwide.
Counterpoint
Investors may be cautious about execution risk for the new flu/COVID combo vaccine and potential regulatory delays.
Key entities
- companyModerna, Inc.
Biotech firm reporting Q3 earnings and new vaccine approvals.
- companyMerck
Partner in Phase 3 melanoma trial mentioned in the release.
